Risk-stratified screening is recommended for perinatal depression and anxiety

What the study found: A staged, risk-stratified screening model is recommended for perinatal depression and anxiety. The abstract says pregnancy-specific anxiety should be assessed alongside depression screening in the second and third trimesters, and that postpartum assessment of sexual function and self-esteem should be added selectively for women with elevated symptoms or psychosocial risk.
Why the authors say this matters: The authors conclude that integrating screening within defined referral pathways may improve detection and enable targeted perinatal mental health care. The study suggests this approach could help identify women who may need additional support.
What the researchers tested: The abstract describes a proposed screening model for perinatal mental health assessment. It focuses on depression screening, pregnancy-specific anxiety, and, postpartum, selective assessment of sexual function and self-esteem in women with elevated symptoms or psychosocial risk.
What worked and what didn't: The abstract states that pregnancy-specific anxiety should be added to depression screening during the second and third trimesters, and that postpartum sexual function and self-esteem assessment should be used selectively for higher-risk women. No comparative results or measures of effectiveness are provided in the available summary.
What to keep in mind: The abstract does not describe sample size, study design details, or statistical outcomes. Limitations are not described in the available summary.

Key points

• A staged, risk-stratified screening model is recommended for perinatal depression and anxiety.
• Pregnancy-specific anxiety should be assessed with depression screening in the second and third trimesters.
• Postpartum sexual function and self-esteem assessment should be added selectively for women with elevated symptoms or psychosocial risk.
• The authors say defined referral pathways may improve detection and support targeted care.
• No comparative effectiveness data are provided in the abstract.